William N. Harwin
About
William N. Harwin is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics.
According to data from OpenAlex, William N. Harwin has authored 21 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 6 papers in Genetics. Recurrent topics in William N. Harwin's work include Lymphoma Diagnosis and Treatment (8 papers), Cancer Treatment and Pharmacology (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). William N. Harwin is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Cancer Treatment and Pharmacology (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). William N. Harwin collaborates with scholars based in United States, United Kingdom and Italy. William N. Harwin's co-authors include Aman U. Buzdar, A Mangalik, Mark L. Steinberg, Alan Webster, Michaël Pollak, G. Burton, Mia von Euler, Jean‐Marc Nabholtz, John D. Hainsworth and Ian W. Flinn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
William N. Harwin
20 papers receiving 828 citations
Hit Papers
Peers
William N. Harwin
Mauro Porpiglia Italy
D. G. Kieback Germany
G. Gardin Italy
Catherine Harper‐Wynne United Kingdom
M. Lassus Switzerland
Ulla Johansson Sweden
P. Neven Belgium
Ermelinda De Maio Italy
R.K. Gregory United Kingdom
J. Carpenter United States
Citations per year, relative to William N. Harwin William N. Harwin (= 1×)
peers
Mauro Porpiglia
Countries citing papers authored by William N. Harwin
Since
Specialization
Citations
This map shows the geographic impact of William N. Harwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William N. Harwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William N. Harwin more than expected).
Fields of papers citing papers by William N. Harwin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by William N. Harwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William N. Harwin. The network helps show where William N. Harwin may publish in the future.
Co-authorship network of co-authors of William N. Harwin
This figure shows the co-authorship network connecting the top 25 collaborators of William N. Harwin. A scholar is included among the top collaborators of William N. Harwin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William N. Harwin. William N. Harwin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bartlett, Nancy L., Christopher A. Yasenchak, William N. Harwin, et al.. (2022). P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY. HemaSphere. 6. 1064–1065.
2.
Bartlett, Nancy L., Christopher A. Yasenchak, William N. Harwin, et al.. (2022). Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.. Journal of Clinical Oncology. 40(16_suppl). 7559–7559.
3.
Bartlett, Nancy L., et al.. (2021). Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. Journal of Clinical Oncology. 39(15_suppl). TPS7571–TPS7571.
4.
Bartlett, Nancy L., et al.. (2021). Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). Blood. 138(Supplement 1). 3564–3564.
5.
Flinn, Ian W., Amy S. Ruppert, William N. Harwin, et al.. (2016). A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. American Journal of Hematology. 91(10). 1020–1025.
6.
Yardley, DA, et al.. (2016). Abstract P1-12-04: A phase 2 study of eribulin in breast cancer not achieving a pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC). Cancer Research. 76(4_Supplement). P1–12.
7.
Yardley, Denise A., Linda D. Bosserman, Joyce O’Shaughnessy, et al.. (2015). Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. Breast Cancer Research and Treatment. 154(1). 89–97.
8.
Yardley, Denise A., Linda D. Bosserman, Mark Keaton, et al.. (2015). TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 33(15_suppl). 1000–1000.
9.
Bendell, Johanna C., James D. Peyton, Henry Q. Xiong, et al.. (2014). A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.. Journal of Clinical Oncology. 32(15_suppl). TPS4163–TPS4163.
10.
Harwin, William N., et al.. (2013). 'Economies of scale' yield multiple benefits for a private, physician-run oncology practice.. PubMed. 27(7). 616, 618, C3–616, 618, C3.
11.
Yardley, Denise A., Zeqiang Ma, Patrick J. Ward, et al.. (2013). Abstract 2397: Correlation between biomarker status and response to EGFR inhibition in triple-negative breast cancer (TNBC): findings from a Phase II trial.. Cancer Research. 73(8_Supplement). 2397–2397.
12.
Binder, G., William N. Harwin, Stephen Stemkowski, et al.. (2012). Drug resource use and costs for novel agents in multiple myeloma.. Journal of Clinical Oncology. 30(15_suppl). e18560–e18560.
13.
Flinn, Ian W., William N. Harwin, Patrick J. Ward, et al.. (2012). Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood. 120(21). 719–719.
14.
Flinn, Ian W., William N. Harwin, Ines Macias‐Perez, et al.. (2011). A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,. Blood. 118(21). 3912–3912.
15.
Yardley, DA, et al.. (2011). TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): Preliminary toxicity of a Sarah Cannon Research Institute phase III trial.. Journal of Clinical Oncology. 29(15_suppl). 1103–1103.
16.
Yardley, DA, Edward Arrowsmith, William N. Harwin, et al.. (2009). Preliminary safety results from a multicenter phase II noncomparative two arm pilot of bevacizumab with anastrozole or fulvestrant as 1st line metastatic breast cancer therapy.. Cancer Research. 69(2_Supplement). 4113–4113.
17.
Peacock, N. W., David R. Spigel, Mark Mainwaring, et al.. (2007). Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1043–1043.
18.
Nabholtz, Jean‐Marc, Aman U. Buzdar, Michaël Pollak, et al.. (2000). Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial. Journal of Clinical Oncology. 18(22). 3758–3767.
19.
Rubenstein, James H., Daniel E. Dosoretz, Michael J. Katin, et al.. (1995). Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung. International Journal of Radiation Oncology*Biology*Physics. 33(2). 329–337.
20.
Blitzer, Peter H., Daniel E. Dosoretz, Michael J. Katin, et al.. (1994). Radiation and chemotherapy. Treatment of localized pancreatic carcinoma.. PubMed. 81(6). 403–7.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mauro Porpiglia Breakdown of academic impact, for papers by D. G. Kieback Breakdown of academic impact, for papers by G. Gardin Breakdown of academic impact, for papers by Catherine Harper‐Wynne Breakdown of academic impact, for papers by M. Lassus Breakdown of academic impact, for papers by Ulla Johansson Breakdown of academic impact, for papers by P. Neven Breakdown of academic impact, for papers by Ermelinda De Maio Breakdown of academic impact, for papers by R.K. Gregory Breakdown of academic impact, for papers by J. Carpenter